Media Center PRESS RELEASE 2017 ELUSYS DELIVERS FIRST SHIPMENT OF ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. GOVERNMENT STRATEGIC NATIONAL STOCKPILE Anthim Lyophilization Program Continues to Advance PINE BROOK, NJ, OCTOBER 10, 2017 – Elusys Therapeutics, Inc. (Elusys) announced today that the company has delivered the first doses of ANTHIM® (obiltoxaximab) Injection, its treatment for inhalational anthrax, to the U.S. Strategic National Stockpile (SNS), the U.S. Government’s repository of critical medical supplies for public health emergency preparedness. The company is providing this delivery of ANTHIM as part of a procurement contract totaling $44.9M issued in 2015 by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (HHS ASPR). ANTHIM received U.S. Food and Drug Administration (FDA) marketing approval in March 2016. ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. Elusys has received over $240M in grants and contracts from the U.S. Department of Defense (DoD), National Institutes of Health (NIH), and BARDA, and is now partnering with the U.S. Centers for Disease Control and Prevention (CDC), which manages the SNS, to ensure that this lifesaving countermeasure can be provided in the event of an anthrax outbreak. “Elusys is proud of our long-standing relationship with the U.S. Government over the past 15 years. Our first delivery of ANTHIM to the SNS marks a major commercial milestone for Elusys and it is a significant achievement for the U.S. Government,” said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. “ANTHIM can now be provided by CDC to treat U.S. citizens, first responders and military personnel in an anthrax emergency.” Elusys also announced today that it continues to make progress in developing an alternate dosage form for ANTHIM with the initiation of a manufacturing campaign to produce material for completion of the lyophilization (freeze drying) commercial process, in addition to providing product to complete the 2015 procurement order. The lyophilized form of ANTHIM is expected to extend product shelf-life by several years. Lyophilization also may improve tolerance of ANTHIM to extreme temperatures during shipping and field use. These improvements should enhance operational flexibility and improve life cycle management for the U.S. Government. ABOUT ANTHIM ANTHIM received U.S. Food and Drug Administration (FDA) marketing approval in March 2016. ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis. The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. There have been no studies of the safety or pharmacokinetics (PK) of ANTHIM in the pediatric population. Dosing in pediatric patients was derived using a population PK approach. ANTHIM does not have direct antibacterial activity. ANTHIM should be used in combination with appropriate antibacterial drugs. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage that leads to death. ANTHIM is supplied as single-dose vials for IV infusion. Anthrax is a life-threatening infectious disease caused by Bacillus anthracis. Cases of inhalational anthrax in humans can occur through intentional spread of B. anthracis spores as a biowarfare or bioterrorism agent. B. anthracis spores introduced through the lungs lead to inhalational anthrax, which is deadly in humans. IMPORTANT SAFETY INFORMATION Including BOXED WARNING WARNING: HYPERSENSITIVITY and ANAPHYLAXIS Hypersensitivity reactions, including anaphylaxis, have been reported during ANTHIM infusion. ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs. WARNINGS AND PRECAUTIONS Hypersensitivity and anaphylaxis have been reported during the IV infusion of ANTHIM. Due to the risk of hypersensitivity and anaphylaxis, ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive ANTHIM closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs. Pre-medication with diphenhydramine is recommended prior to administration of ANTHIM. Diphenhydramine pre-medication does not prevent anaphylaxis, and may mask or delay onset of symptoms of hypersensitivity. ADVERSE REACTIONS The safety of ANTHIM has been studied only in healthy volunteers. It has not been studied in patients with inhalational anthrax. The most frequently reported adverse reactions were headache, pruritus, infections of the upper respiratory tract, cough, vessel puncture site bruise, infusion site swelling, urticaria, nasal congestion, infusion site pain, and pain in extremity. USE IN SPECIFIC POPULATIONS Pediatric Use: There have been no studies of the safety or PK of ANTHIM in the pediatric population. To see the complete prescribing information for ANTHIM, click here. About Elusys Therapeutics, Inc. Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of infectious disease. In March 2016, the U.S. Food and Drug Administration (FDA) approved ANTHIM (obiltoxaximab) Injection (www.anthim.com), the company’s monoclonal antibody (mAb) anthrax antitoxin, for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. Elusys has received over $240M in development grants and contracts from the U.S. Department of Defense (DoD), National Institutes of Health (NIH) and BARDA. Current investors include EW Healthcare Partners, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information, visit www.elusys.com. The ANTHIM program was supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services (HHS) under Contracts Numbers HHSO100201000026C, funded at $140.9 million, and HHS0100201100034C, funded at $62.5 million. The first delivery order for ANTHIM valued at $ 44.9 million was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), within the Department of Health and Human Services (HHS) under Contract No. HHSO100201300010I. CONTACT: Gina Cella Cella Communications t: 857-239-9198 e: ginacella@comcast.net SAFE HARBOR STATEMENT This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. This release includes forward looking statements. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. Such statements are based upon the current beliefs and expectations of management that are subject to risks, uncertainties and other important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. View All Press Releases About Us What We Do Our Products Leadership Executive Team Board of Directors Our Partners About Anthrax What is anthrax? The threat of anthrax Transmission and spread of anthrax Symptoms of inhalation anthrax Anthrax Treatment Media Center Press Releases Resources and Links Publications Contact Us Site Map Privacy Terms And Conditions Copyright 2021 Elusys Therapeutics, Inc. All Rights Reserved.